These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16569372)

  • 1. Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers.
    Hummers LK
    Curr Rheumatol Rep; 2006 Apr; 8(2):131-7. PubMed ID: 16569372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum uric acid as a marker of microvascular damage in systemic sclerosis patients.
    Gigante A; Barbano B; Barilaro G; Quarta S; Gasperini ML; Di Mario F; Romaniello A; Amoroso A; Cianci R; Rosato E
    Microvasc Res; 2016 Jul; 106():39-43. PubMed ID: 27003713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of vascular disease in scleroderma.
    Hummers LK
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v21-2. PubMed ID: 18784132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study.
    Reiseter S; Molberg Ø; Gunnarsson R; Lund MB; Aalokken TM; Aukrust P; Ueland T; Garen T; Brunborg C; Michelsen A; Abraityte A; Hoffmann-Vold AM
    Arthritis Res Ther; 2015 Aug; 17(1):231. PubMed ID: 26315510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular involvement in systemic sclerosis (SSc).
    Kahaleh MB
    Clin Exp Rheumatol; 2004; 22(3 Suppl 33):S19-23. PubMed ID: 15344592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers in systemic sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Settas L; Kitas GD
    Curr Vasc Pharmacol; 2011 Mar; 9(2):213-9. PubMed ID: 21143174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis.
    Allanore Y; Distler O; Matucci-Cerinic M; Denton CP
    Arthritis Rheumatol; 2018 Feb; 70(2):162-170. PubMed ID: 29145709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcome in systemic sclerosis.
    Voilliot D; Magne J; Dulgheru R; Kou S; Henri C; Caballero L; De Sousa C; Sprynger M; Andre B; Pierard LA; Lancellotti P
    Acta Cardiol; 2015 Oct; 70(5):554-63. PubMed ID: 26567815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parasympathetic activity increases with digital microvascular damage and vascular endothelial growth factor in systemic sclerosis.
    Gigante A; Margiotta D; Navarini L; Liberatori M; Barbano B; Tubani L; Afeltra A; Rosato E
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):24-27. PubMed ID: 29787366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma endothelial microparticles reflect the extent of capillaroscopic alterations and correlate with the severity of skin involvement in systemic sclerosis.
    Michalska-Jakubus M; Kowal-Bielecka O; Smith V; Cutolo M; Krasowska D
    Microvasc Res; 2017 Mar; 110():24-31. PubMed ID: 27889559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review.
    Paxton D; Pauling JD
    Semin Arthritis Rheum; 2018 Dec; 48(3):482-494. PubMed ID: 29602558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between bone quality and microvascular damage in systemic sclerosis patients.
    Ruaro B; Casabella A; Paolino S; Pizzorni C; Alessandri E; Seriolo C; Botticella G; Molfetta L; Odetti P; Smith V; Cutolo M
    Rheumatology (Oxford); 2018 Sep; 57(9):1548-1554. PubMed ID: 29788459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular complications of scleroderma.
    Guiducci S; Giacomelli R; Cerinic MM
    Autoimmun Rev; 2007 Sep; 6(8):520-3. PubMed ID: 17854742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities.
    Riccieri V; Rinaldi T; Spadaro A; Scrivo R; Ceccarelli F; Franco MD; Taccari E; Valesini G
    Clin Rheumatol; 2003 May; 22(2):102-6. PubMed ID: 12740673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of vascular disease biomarkers for digital ulcers in systemic sclerosis patients.
    Silva I; Teixeira A; Oliveira J; Almeida I; Almeida R; Vasconcelos C
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S127-30. PubMed ID: 26242908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vascular manifestations in systemic sclerosis (scleroderma)].
    Cafagna D; Melon F; Balbi M; Ponte E
    Minerva Med; 1998 May; 89(5):153-61. PubMed ID: 9676180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis.
    Del Papa N; Colombo G; Fracchiolla N; Moronetti LM; Ingegnoli F; Maglione W; Comina DP; Vitali C; Fantini F; Cortelezzi A
    Arthritis Rheum; 2004 Apr; 50(4):1296-304. PubMed ID: 15077314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the diagnosis and management of scleroderma-related vascular complications.
    Kerin K; Yost JH
    Compr Ther; 1998; 24(11-12):574-81. PubMed ID: 9847974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
    Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body composition and microvascular damage in systemic sclerosis patients.
    Gigante A; Rosato E; Muscaritoli M
    J Endocrinol Invest; 2021 Jan; 44(1):205-206. PubMed ID: 32683616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.